on Dogwood Therapeutics, Inc. (NASDAQ:DWTX)
Dogwood Therapeutics to Announce Q3 2025 Financial Results
Dogwood Therapeutics, Inc., a biotechnology company specializing in novel pain and neuropathy treatments, is set to disclose its financial outcomes for the third quarter of 2025. The announcement will occur on Thursday, November 6, before financial markets open. This event marks a significant step for the Nasdaq-listed company as it continues advancing its pharmaceutical pipeline.
Dogwood's development efforts are currently centered around two primary drug candidates: Halneuron® and SP16 IV. Halneuron® is in the Phase 2b stage, focusing on treating neuropathy pain linked to chemotherapy. Notably, it carries a fast-track designation by the FDA, aiming to offer non-opioid pain relief. Meanwhile, SP16 IV, also showing promise for treating neuropathy, is preparing for a Phase 1b trial, supported by the National Cancer Institute.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Dogwood Therapeutics, Inc. news